Self-pay options for Wegovy without insurance

If you’ve been researching GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably noticed the price tags—often over $1,000 per month without insurance. The big question on everyone’s mind: Does insurance actually cover these medications?

The answer is complicated. While these drugs can be life-changing for weight management, insurance coverage remains inconsistent and frustrating for many patients. Understanding the coverage landscape can help you navigate approvals, appeals, and alternative payment options.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, it’s important to understand what we’re talking about. Three main GLP-1 medications dominate the conversation:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight adults (BMI ≥27) who have at least one weight-related health condition like high blood pressure or type 2 diabetes.

Ozempic (semaglutide) is the same active ingredient as Wegovy but is FDA-approved only for type 2 diabetes management. Many people use it off-label for weight loss, which creates insurance coverage challenges.

Mounjaro (tirzepatide) is also FDA-approved for type 2 diabetes. Its weight-loss counterpart, Zepbound, received FDA approval for obesity in 2023.

This distinction matters enormously for insurance coverage. Insurers typically cover medications for their FDA-approved indications—meaning Ozempic and Mounjaro get covered for diabetes, while Wegovy coverage for weight loss faces significant barriers.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: A Patchwork System

Does Private Insurance Cover Wegovy?

The short answer: Sometimes, but with major restrictions.

Most commercial insurers treat anti-obesity medications as ‘optional’ benefits rather than essential health services. According to a 2024 KFF survey, many employer-sponsored plans exclude weight-loss drugs entirely due to their high cost. When coverage does exist, it comes with strict requirements.

Plans that do cover Wegovy typically require:

• BMI threshold: Usually BMI ≥30, or BMI ≥27 with at least one obesity-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• Documented weight-loss attempts: Proof of at least 6 months of supervised diet and exercise programs
• Prior authorization: Nearly universal requirement with extensive documentation
• Step therapy: Many insurers require trying older, cheaper weight-loss medications first
• Ongoing monitoring: Continued coverage depends on achieving weight-loss goals (often ≥5% body weight reduction within 3-6 months)

Coverage for Ozempic and Mounjaro (Diabetes Indication)

Insurance coverage is far more straightforward when these medications are prescribed for their FDA-approved diabetes indication. Most commercial plans cover Ozempic and Mounjaro for type 2 diabetes management, though prior authorization is common to confirm diagnosis and ensure appropriate use.

However, if you’re seeking these medications solely for weight loss without diabetes, insurers will typically deny coverage—even with prior authorization. They’ll often direct you to Wegovy instead (if your plan covers obesity treatment at all).

Medicare Coverage: Limited Options

The Federal Exclusion

Here’s a critical fact many people don’t realize: Medicare Part D does not cover medications for weight loss or obesity treatment. This exclusion is written into federal law under the Social Security Act.

The only exception came in March 2024, when Medicare announced it would cover Wegovy specifically for cardiovascular risk reduction in obese patients with established heart disease. This narrow indication means Medicare beneficiaries can access Wegovy only if prescribed to prevent heart attacks and strokes—not for weight management alone.

Medicare does cover Ozempic and Mounjaro for their approved diabetes uses, typically placing them in Tier 3 (non-preferred brand) with corresponding copays or coinsurance.

What About Medicare Advantage?

Some Medicare Advantage plans began offering limited coverage for anti-obesity medications in 2025, though this remains uncommon and highly restricted. If you have Medicare Advantage, check your specific plan’s formulary, as coverage varies significantly by insurer and region.

Medicaid Coverage: State-by-State Variation

Medicaid coverage for weight-loss medications is perhaps the most confusing aspect of the insurance landscape, with dramatic differences from state to state.

States That Cover Wegovy (With Restrictions)

As of December 2025, only about 13 states offer any Medicaid coverage for GLP-1 weight-loss medications—and that number is shrinking due to budget constraints.

New York covers Wegovy through its NYRx formulary with prior authorization. Criteria include BMI ≥30 or BMI ≥27 with comorbidities, documented lifestyle modification efforts, and quantity limits.

Pennsylvania added coverage in 2023 with strict requirements: BMI ≥30 (or ≥27 plus one comorbidity), documented weight-related health conditions, and proof of diet/exercise attempts. However, Pennsylvania is discontinuing this coverage in January 2026 due to budget impacts—a trend affecting multiple states.

States With No Coverage

California covered Wegovy with prior authorization through 2025, but the state announced that all GLP-1 weight-loss medications will be removed from Medi-Cal coverage effective January 1, 2026. This budget-driven decision affects thousands of current users.

Texas excludes all obesity medications for adults 21 and older under its Medicaid program, citing the optional federal exclusion. Wegovy, Saxenda, and similar drugs are considered non-formulary.

Florida similarly does not cover anti-obesity medications through Medicaid, utilizing the federal exclusion provision.

Illinois has not adopted coverage for obesity drugs in its Medicaid program as of 2025, though the state expanded coverage for state employees separately.

This patchwork creates significant health inequities, as Medicaid enrollees in most states have no path to affordable GLP-1 weight-loss medications.

How to Navigate Prior Authorization

If your insurance offers potential coverage, you’ll almost certainly face prior authorization. Here’s how to maximize your approval chances:

What You’ll Need

Your healthcare provider will need to submit extensive documentation, including:

• Current height, weight, and calculated BMI
• Complete medical history showing weight-related health conditions
• Records of previous weight-loss attempts (diet programs, exercise regimens, behavioral therapy)
• Lab results showing relevant comorbidities
• A detailed letter of medical necessity explaining why this medication is appropriate

Common Denial Reasons

Understanding why claims get denied helps you avoid these pitfalls:

1. Insufficient BMI documentation: Your recorded BMI doesn’t meet threshold requirements
2. Lack of lifestyle intervention records: No documentation of the required 6-month supervised diet and exercise program
3. Missing comorbidity diagnosis: For BMI 27-29.9, lacking documentation of required weight-related conditions
4. Failure to try alternatives: Not attempting cheaper weight-loss medications or older GLP-1s first
5. Off-label use: Requesting Ozempic for weight loss when you don’t have diabetes
6. Plan exclusion: Your policy categorically excludes obesity treatment drugs

The Appeals Process

If your initial request is denied, don’t give up. The appeals process often succeeds when patients truly meet criteria but documentation was incomplete.

First-level appeal: Usually reviewed within 5-7 business days. Your provider should submit additional documentation addressing the specific denial reason.

Second-level appeal: If denied again, request an external review. This involves an independent medical reviewer who assesses whether the denial was appropriate.

Success rates vary by insurer, but appeals with strong clinical documentation—especially for patients with BMI ≥35 and multiple comorbidities—often get approved on reconsideration.

Medication Coverage Comparison

To help you understand your options, here’s how coverage typically breaks down:

Self-Pay Options: Making Treatment Affordable

If insurance won’t cover your medication—or if you’re still working through appeals—several options can significantly reduce costs.

GoodRx Partnership with Novo Nordisk

In November 2025, GoodRx announced a groundbreaking pricing program for Wegovy and Ozempic:

• $199 per month for your first two fills
• $349 per month for ongoing treatment

This represents approximately 60-70% off the standard retail price of $1,000-$1,350 per month. The program is available at most pharmacies nationwide and doesn’t require insurance.

Manufacturer Savings Cards

Novo Nordisk offers a savings card for commercially insured patients that can reduce Wegovy copays to as low as $0, with up to $225 off per month. The card typically works even if your insurance doesn’t cover the medication, though you’ll need at least partial insurance processing.

For Ozempic (diabetes use), Novo’s savings card can reduce copays to $25 per month for eligible patients.

Eli Lilly provides a savings card for Mounjaro that reduces copays to $25 monthly for insured patients with type 2 diabetes (covers up to approximately $500 off).

Note: These manufacturer savings programs cannot be used with government insurance (Medicare, Medicaid) due to federal anti-kickback regulations.

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer patient assistance programs (PAPs) for uninsured or underinsured individuals who meet income requirements. If approved, you may receive medication at no cost for up to one year.

Eligibility typically requires:

• Lack of prescription drug coverage
• Household income below 400% of the federal poverty level (approximately $60,000 for an individual)
• U.S. residency and citizenship documentation

Lilly’s Direct-to-Consumer Program

Eli Lilly launched LillyDirect in late 2025, offering single-dose vials of Zepbound (tirzepatide for weight loss) at reduced prices:

• 2.5 mg vials: $299/month (down from $549)
• 5 mg vials: $399/month (down from $649)
• 7.5 mg and higher: $449-$549/month

This program bypasses traditional pharmacies and ships directly to patients.

Telehealth and Insurance: What You Need to Know

One of the biggest questions patients have: Will insurance cover telehealth visits for weight-loss treatment?

The good news is that telehealth coverage has expanded dramatically since 2020. More than 40 states now have parity laws requiring private insurers to cover telehealth services on equal footing with in-person visits.

What Insurers Typically Cover

Most commercial plans now cover:

• Virtual consultations with healthcare providers for weight management
• Nutritional counseling via telemedicine (often covered as preventive care under the ACA)
• Follow-up appointments for medication monitoring

Medicare also expanded telehealth coverage and continues to reimburse for virtual visits with established providers.

Important Considerations

Network requirements: Your telehealth provider usually needs to be in-network for insurance to cover the visit. Some platforms operate outside insurance networks, offering cash-pay visits even if your medication prescription might be covered.

Visit format: Most insurers require live video consultations for full coverage. Phone-only or asynchronous messaging may have different coverage rules.

Prescription coverage: Even if the telehealth visit is covered by insurance, the medication prescription still faces the same formulary and prior authorization requirements discussed earlier.

At Klarity Health, we understand these insurance complexities. Our platform connects you with experienced healthcare providers who can evaluate your needs, provide necessary documentation for prior authorizations, and help you access treatment—whether through insurance or affordable self-pay options. We accept both insurance and cash payment, with transparent pricing and flexible appointment availability that works with your schedule.

Special Situations and Coverage Exceptions

Dual Eligibles (Medicare + Medicaid)

If you have both Medicare and Medicaid coverage, your state’s Medicaid program may cover Wegovy for weight loss even though Medicare doesn’t. This has been confirmed in states like Pennsylvania, where dual-eligible beneficiaries could access coverage through their Medicaid benefit.

However, this window is closing as states drop coverage due to budget pressures.

Pediatric Coverage (EPSDT)

Children and adolescents under 21 enrolled in Medicaid may qualify for coverage under Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits, even in states that exclude obesity drugs for adults.

Wegovy is FDA-approved for adolescents ages 12 and older with obesity, and pediatric patients may request case-by-case exceptions through EPSDT provisions.

Employer Self-Funded Plans

If you have insurance through a large employer with a self-funded plan, coverage may differ from standard commercial policies. Some progressive employers have begun adding obesity treatment coverage recognizing the long-term health benefits and cost savings.

Check your specific Summary of Benefits and Coverage (SBC) document to understand your plan’s policy on weight-loss medications.

The Future of Coverage: What’s Coming

The landscape for GLP-1 coverage continues to evolve rapidly:

Legislative pressure: There’s growing advocacy for Congress to remove the Medicare Part D exclusion for obesity medications, which would extend coverage to millions of seniors. Several bills have been introduced, though passage remains uncertain.

State Medicaid decisions: The trend currently runs toward reducing coverage due to budget constraints, with California and Pennsylvania eliminating coverage in 2026. However, advocacy groups continue pushing for recognition of obesity as a chronic disease requiring medical treatment.

Manufacturer pricing: Novo Nordisk and Eli Lilly have both announced significant price reductions for self-pay patients in late 2025, partly in response to political pressure and competition from compounded alternatives. This trend may continue.

Biosimilar development: Once patents expire in the 2030s, biosimilar versions of these medications should dramatically reduce costs and potentially expand insurance coverage.

Making Your Coverage Work: Practical Steps

1. Verify Your Specific Coverage

Don’t rely on general information—call your insurance company’s pharmacy benefits line and ask specifically:

• Is Wegovy (or the medication you’re considering) on the formulary?
• What tier is it placed in?
• What are the prior authorization requirements?
• Are there step therapy requirements?
• What will my out-of-pocket cost be if approved?

2. Work With Your Healthcare Provider

Choose a provider experienced with GLP-1 medications and insurance navigation. They should be familiar with:

• Documenting medical necessity
• Completing prior authorization forms thoroughly
• Writing compelling letters of medical necessity
• Managing appeals when needed

Telehealth platforms like Klarity Health specialize in weight management and have providers who understand the documentation requirements for insurance approval.

3. Document Everything

Keep your own records of:

• Weight measurements over time
• Diet and exercise programs you’ve tried
• Comorbid conditions and related lab work
• All communication with your insurance company

This documentation supports appeals and demonstrates your commitment to weight management.

4. Explore All Payment Options

Create a payment strategy that considers:

• Insurance coverage with copay assistance
• Manufacturer savings cards
• GoodRx programs
• Patient assistance programs
• Health Savings Account (HSA) or Flexible Spending Account (FSA) funds

5. Consider Clinical Trial Participation

Some research studies offer free medication and monitoring for participants. Check ClinicalTrials.gov for opportunities in your area studying GLP-1 medications for weight management.

When to Consider Alternatives

If you’ve exhausted insurance options and self-pay pricing remains unaffordable, discuss these alternatives with your provider:

Older weight-loss medications like phentermine, orlistat, or combination products (Qsymia, Contrave) cost $30-$150 monthly and have better insurance coverage.

Lifestyle medicine programs combining nutrition counseling, behavioral therapy, and exercise may be covered as preventive services under your plan.

Surgical options like bariatric surgery often have better insurance coverage for qualified patients, with many plans covering these procedures when medical criteria are met.

Remember that weight management is a long-term journey, and the most effective approach combines medication (when appropriate) with sustainable lifestyle changes.

Take Control of Your Health Journey

Navigating insurance coverage for GLP-1 weight-loss medications requires persistence, documentation, and often creativity. While the current system remains frustrating and inequitable, understanding your options empowers you to make informed decisions.

Whether you’re working through insurance approvals, appealing a denial, or exploring self-pay options, you don’t have to figure it out alone. Healthcare providers experienced in weight management can guide you through the process, provide necessary documentation, and help you access treatment.

Ready to explore your options for weight-loss treatment? Klarity Health offers convenient telehealth consultations with providers who specialize in weight management and understand insurance navigation. With both insurance billing and transparent cash-pay pricing, flexible appointment times, and ongoing support, we make accessing quality care straightforward. Schedule your consultation today to discuss whether GLP-1 medications are right for you and create a personalized plan that fits your budget and insurance situation.

Frequently Asked Questions

Does insurance cover Wegovy for weight loss?

Coverage varies significantly. Many commercial plans offer limited coverage with strict prior authorization requirements (BMI ≥30 or ≥27 with comorbidities, documented lifestyle attempts). Medicare Part D does not cover Wegovy for weight loss alone. Most state Medicaid programs don’t cover it, and several states that did are eliminating coverage in 2026.

Can I use Ozempic for weight loss if my insurance covers it for diabetes?

Insurers typically deny coverage when Ozempic is prescribed solely for weight loss without a diabetes diagnosis. This off-label use isn’t covered even with prior authorization. If you have type 2 diabetes, Ozempic will be covered for that indication, and weight loss may occur as a beneficial side effect.

What if my insurance denies coverage for Wegovy?

You have several options: (1) Appeal the denial with additional documentation, (2) Use manufacturer savings programs like Novo’s $349/month self-pay price or GoodRx’s $199-349/month program, (3) Apply for patient assistance programs if you meet income requirements, or (4) Discuss alternative weight-loss medications with better coverage.

How much does Wegovy cost without insurance?

The list price is approximately $1,350 per month. However, new self-pay programs have dramatically reduced costs: GoodRx offers $199/month for the first two months, then $349/month ongoing. Novo Nordisk’s direct program also offers $349/month pricing. These represent significant discounts from retail prices.

Will my insurance cover telehealth visits for weight-loss treatment?

Most commercial insurers and Medicare now cover telehealth consultations for weight management on equal footing with in-person visits, thanks to expanded coverage policies and state parity laws. However, verify that your telehealth provider is in-network, and note that visit coverage doesn’t automatically mean medication coverage—prescriptions still face formulary restrictions.

Research Currency Statement

Verified as of December 17, 2025

Top Sources:

1. California Department of Health Care Services (DHCS) – Medi-Cal announcement regarding GLP-1 coverage discontinuation (December 2025) – www.cmadocs.org

2. Kaiser Family Foundation (KFF) – Issue Brief on Medicaid Coverage of GLP-1 Medications (November 2024) – www.kff.org

3. GoodRx Press Release – Announcement of $199/month introductory pricing program for Wegovy and Ozempic (November 2025) – www.businesswire.com

4. Pennsylvania Health Law Project (PHLP) – Pennsylvania Medicaid coverage criteria and 2026 changes (August 2024, updated December 2025) – www.phlp.org

5. Fierce Pharma – Manufacturer pricing updates from Novo Nordisk and Eli Lilly (November and December 2025) – www.fiercepharma.com

Coverage policies and pricing are subject to change. Always verify current information with your specific insurance plan and pharmacy.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499